Serum Inflammatory Markers as Classifiers of Lung Cancer Mortality

Lung cancer remains the number one cause of cancer deaths worldwide. Early detection of lung cancer remains the most effective method to improve patient prognosis, and the recent adoption of low-dose CT (LDCT) imaging in high-risk lung cancer individuals has resulted in increased detection of stage I lung cancer. Most patients respond completely to surgery, the standard of care for stage I lung cancer, but approximately 30% of patients diagnosed with stage I develop recurrence which leads to mortality.

There exists a need for a diagnostic test that will identify patients with early stage lung cancer with a greater likelihood for recurrence. By stratifying patients, physicians can reassure patients that their cancer will not relapse after surgery, or recommend more aggressive therapeutic strategies. Recent work at the NCI has identified that circulating levels of the cytokines IL-6 and IL-17 are predictive of early stage lung cancer prognosis.

Available for licensing and collaborative development are methods of determining prognosis in early stage lung cancer by measuring serum levels of IL-6 and IL-17.

Potential Commercial Applications: Competitive Advantages:
  • Prognostic biomarker test to identify risk of stage I lung cancer recurrence
  • There are no known prognostic tests for stage I lung cancer, despite recurrence in 30% of patients
  • Blood based test offers a non-invasive method to screen patients

Development Stage:
Discovery (Lead Identification)

Related Invention(s):


Brid Ryan (NCI)  ➽ more inventions...

Intellectual Property:
US Provisional Application No. 62/412,690

CL Meaney et al. Identification of serum inflammatory markers as classifiers of lung cancer mortality for stage I adenocarcinoma  PMID: 28402963

Collaboration Opportunity:

Licensing and research collaboration

Licensing Contact:
John Hewes, Ph.D.
Phone: 240-276-5515

OTT Reference No: E-283-2016
Updated: Jun 16, 2017